Lazertinib with stereotactic body radiotherapy in oligometastatic EGFR-mutant non-small-cell lung cancer.
[BACKGROUND] Lazertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that demonstrated progression-free survival (PFS) benefit in treatment-naive, EGFR
- 표본수 (n) 34
- 추적기간 23.1 months
APA
Lee JB, Kim KH, et al. (2026). Lazertinib with stereotactic body radiotherapy in oligometastatic EGFR-mutant non-small-cell lung cancer.. ESMO open, 11(2), 106057. https://doi.org/10.1016/j.esmoop.2025.106057
MLA
Lee JB, et al.. "Lazertinib with stereotactic body radiotherapy in oligometastatic EGFR-mutant non-small-cell lung cancer.." ESMO open, vol. 11, no. 2, 2026, pp. 106057.
PMID
41604814
Abstract
[BACKGROUND] Lazertinib is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that demonstrated progression-free survival (PFS) benefit in treatment-naive, EGFR-mutant advanced non-small-cell lung cancer (NSCLC) as a single agent and in combination with amivantamab. Here, we report the clinical efficacy and safety profile of lazertinib plus stereotactic body radiotherapy (SBRT) in treatment-naive, EGFR-mutant oligometastatic NSCLC.
[PATIENTS AND METHODS] ABLATE is a phase II, multicenter, randomized, non-comparative study that included patients harboring activating EGFR mutations (ex19del or L858R) with synchronous oligometastatic disease (metastatic lesion ≤5). Patients received oral lazertinib 240 mg as monotherapy or in combination with SBRT, which was given immediately or 8 weeks after initiation of lazertinib. The primary endpoint was investigator-assessed PFS of lazertinib plus SBRT.
[RESULTS] A total of 67 patients were enrolled in the study (n = 34, lazertinib; n = 33, lazertinib plus SBRT). At a median follow-up duration of 23.1 months (range 7.1-34.1 months), the median PFS was 34.0 months [90% confidence interval (CI) 19.2 months-not reached (NR)] and objective response rate (ORR) was 58% (95% CI 40.7% to 74.4%) for the lazertinib plus SBRT group. In lazertinib monotherapy, the median duration of follow-up was 22.4 months (range 3.7-33.5 months), the median PFS was 24.8 months (90% CI 15.7 months-NR), and ORR was 68% (95% CI 51.9% to 83.4%). SBRT led to local treatment effect with 92% (n = 12/14) progressing to new sites at progression. No new safety signals were seen with the addition of SBRT, and no grade ≥3 radiation pneumonitis was seen. Whole-exome sequencing of baseline tumor samples revealed that TP53 (64%), CRLF2 (43%), and P2RY9 (43%) were the most common mutations in patients treated with lazertinib plus SBRT.
[CONCLUSION] In treatment-naive, EGFR-mutant oligometastatic NSCLC, adding upfront SBRT to lazertinib is a viable therapeutic option with a manageable safety profile.
[PATIENTS AND METHODS] ABLATE is a phase II, multicenter, randomized, non-comparative study that included patients harboring activating EGFR mutations (ex19del or L858R) with synchronous oligometastatic disease (metastatic lesion ≤5). Patients received oral lazertinib 240 mg as monotherapy or in combination with SBRT, which was given immediately or 8 weeks after initiation of lazertinib. The primary endpoint was investigator-assessed PFS of lazertinib plus SBRT.
[RESULTS] A total of 67 patients were enrolled in the study (n = 34, lazertinib; n = 33, lazertinib plus SBRT). At a median follow-up duration of 23.1 months (range 7.1-34.1 months), the median PFS was 34.0 months [90% confidence interval (CI) 19.2 months-not reached (NR)] and objective response rate (ORR) was 58% (95% CI 40.7% to 74.4%) for the lazertinib plus SBRT group. In lazertinib monotherapy, the median duration of follow-up was 22.4 months (range 3.7-33.5 months), the median PFS was 24.8 months (90% CI 15.7 months-NR), and ORR was 68% (95% CI 51.9% to 83.4%). SBRT led to local treatment effect with 92% (n = 12/14) progressing to new sites at progression. No new safety signals were seen with the addition of SBRT, and no grade ≥3 radiation pneumonitis was seen. Whole-exome sequencing of baseline tumor samples revealed that TP53 (64%), CRLF2 (43%), and P2RY9 (43%) were the most common mutations in patients treated with lazertinib plus SBRT.
[CONCLUSION] In treatment-naive, EGFR-mutant oligometastatic NSCLC, adding upfront SBRT to lazertinib is a viable therapeutic option with a manageable safety profile.
같은 제1저자의 인용 많은 논문 (4)
- A Phase 2 Study of Stereotactic Ablative Radiotherapy Plus Atezolizumab Plus Tiragolumab in Treatment-naïve Patients with Advanced Non-small Cell Lung Cancer.
- Spatially Controlled Capture and Site-Resolved Analysis of Single Extracellular Vesicles.
- Corrigendum to 'Lazertinib with stereotactic body radiotherapy in oligometastatic EGFR-mutant non-small-cell lung cancer': [ESMO Open. Volume 11, Issue 2, February 2026, 106057].
- Lower facial contouring surgery using a novel method: M-genioplasty.